Jefferies Group LLC Athira Pharma, Inc. Call Options Transaction History

Jefferies Group LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Sep 21, 2023	BUY	$2.74 - $13.43 $186,046 - $911,897	67,900 Added 271.6%	92,900 $283,000
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $186,046 - $911,897	67,900 Added 271.6%	92,900 $283,000
Q1 2022 Sep 21, 2023	SELL	$8.96 - $13.51 $224,000 - $337,750	-25,000 Reduced 50.0%	25,000 $337,000
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $224,000 - $337,750	-25,000 Reduced 50.0%	25,000 $338,000
Q4 2021 Sep 21, 2023	BUY	$9.17 - $16.39 $458,500 - $819,500	50,000 New	50,000 $651,000
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $458,500 - $819,500	50,000 New	50,000 $652,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.